Pasar al contenido principal

IDENTIFICACION DE MECANISMOS REGULADORES PARA LA PROTEINA QUINASA DYRK1A Y DE NUEVAS ACTIVIDADES FUNCIONALES

BFU2016-76141-P

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO CENTRE DE REGULACIO GENOMICA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia Maria, 1981-
  • Barallobre, María José
  • Di Vona, Chiara, 1981-
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat i Fonts, Cristina
  • Arbonés de Rafael, Maria Lourdes, 1959-
  • Graupera, Mariona
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Luna Gargantilla, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis., This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), “La Marató de TV3” to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European CommissionFP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Skłodowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011-045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011-11140), and A.F.F. is a Marie Skłodowska-Curie ESR fellow.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response

  • Roewenstrunk, Julia Maria, 1981-
  • Di Vona, Chiara, 1981-
  • Chen, Jie
  • Borràs, Eva
  • Dong, Chao
  • Arató, Krisztina, 1981-
  • Sabidó Aguadé, Eduard, 1981-
  • Huen, Michael S. Y.
  • Luna Gargantilla, Susana de la
Dysregulation of the DYRK1A protein kinase has been associated with human disease. On the one hand, its overexpression in trisomy 21 has been linked to certain pathological traits of Down syndrome, while on the other, inactivating mutations in just one allele are responsible for a distinct yet rare clinical syndrome, DYRK1A haploinsufficiency. Moreover, altered expression of this kinase may also provoke other human pathologies, including cancer and diabetes. Although a few DYRK1A substrates have been described, its upstream regulators and downstream targets are still poorly understood, an information that could shed light on the functions of DYRK1A in the cell. Here, we carried out a proteomic screen using antibody-based affinity purification coupled to mass spectrometry to identify proteins that directly or indirectly bind to endogenous DYRK1A. We show that the use of a cell line not expressing DYRK1A, generated by CRISPR/Cas9 technology, was needed in order to discriminate between true positives and non-specific interactions. Most of the proteins identified in the screen are novel candidate DYRK1A interactors linked to a variety of activities in the cell. The in-depth characterization of DYRK1A's functional interaction with one of them, the E3 ubiquitin ligase RNF169, revealed a role for this kinase in the DNA damage response. We found that RNF169 is a DYRK1A substrate and we identified several of its phosphorylation sites. In particular, one of these sites appears to modify the ability of RNF169 to displace 53BP1 from sites of DNA damage. Indeed, DYRK1A depletion increases cell sensitivity to ionizing irradiation. Therefore, our unbiased proteomic screen has revealed a novel activity of DYRK1A, expanding the complex role of this kinase in controlling cell homeostasis., This work was supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) BFU2013-44513 and BFU2016-76141-P, and the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674). Proteomic analysis was carried out at the CRG/UPF Proteomics Unit, a member of the ProteoRed PRB3 consortium that is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. J.R. is a FPI predoctoral fellow (BES-2011-045867). We also acknowledge the support of the Generalitat de Catalunya: CERCA Programme and Grups de Recerca Reconocida Programme (2017SGR595 and 2017SGR1163)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The DYRK family of kinases in cancer: molecular functions and therapeutic opportunities

  • Boni, Jacopo, 1987-
  • Rubio Pérez, Carlota, 1990-
  • López Bigas, Núria
  • Fillat i Fonts, Cristina
  • Luna, Susana de la
DYRK (dual-specificity tyrosine-regulated kinases) are an evolutionary conserved family of protein kinases with members from yeast to humans. In humans, DYRKs are pleiotropic factors that phosphorylate a broad set of proteins involved in many different cellular processes. These include factors that have been associated with all the hallmarks of cancer, from genomic instability to increased proliferation and resistance, programmed cell death, or signaling pathways whose dysfunction is relevant to tumor onset and progression. In accordance with an involvement of DYRK kinases in the regulation of tumorigenic processes, an increasing number of research studies have been published in recent years showing either alterations of DYRK gene expression in tumor samples and/or providing evidence of DYRK-dependent mechanisms that contribute to tumor initiation and/or progression. In the present article, we will review the current understanding of the role of DYRK family members in cancer initiation and progression, providing an overview of the small molecules that act as DYRK inhibitors and discussing the clinical implications and therapeutic opportunities currently available., J.B. is an FPI predoctoral fellow (BES-2014-069983). De la Luna’s lab is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-76141-P, AEI/FEDER), the AGAUR grant from Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya (SGR14/674) and the CIBER de Enfermedades Raras. We thank La Marato of TV3 for its support to our research in cancer. We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the support of the CERCA Programme/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Loss of the DYRK1A Protein Kinase Results in the Reduction in Ribosomal Protein Gene Expression, Ribosome Mass and Reduced Translation

  • Di Vona, Chiara, 1981-
  • Barba Moreno, Laura, 1989-
  • Ferrari, Roberto
  • Luna, Susana de la
Ribosomal proteins (RPs) are evolutionary conserved proteins that are essential for protein translation. RP expression must be tightly regulated to ensure the appropriate assembly of ribosomes and to respond to the growth demands of cells. The elements regulating the transcription of RP genes (RPGs) have been characterized in yeast and Drosophila, yet how cells regulate the production of RPs in mammals is less well understood. Here, we show that a subset of RPG promoters is characterized by the presence of the palindromic TCTCGCGAGA motif and marked by the recruitment of the protein kinase DYRK1A. The presence of DYRK1A at these promoters is associated with the enhanced binding of the TATA-binding protein, TBP, and it is negatively correlated with the binding of the GABP transcription factor, establishing at least two clusters of RPGs that could be coordinately regulated. However, DYRK1A silencing leads to a global reduction in RPGs mRNAs, pointing at DYRK1A activities beyond those dependent on its chromatin association. Significantly, cells in which DYRK1A is depleted have reduced RP levels, fewer ribosomes, reduced global protein synthesis and a smaller size. We therefore propose a novel role for DYRK1A in coordinating the expression of genes encoding RPs, thereby controlling cell growth in mammals., This research was supported by the Spanish Ministry of Science and Innovation (BFU2016-76141-P, PID2019-107185GB-I00, AEI/FEDER) and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya (grant number 2021SGR01229) to S.d.l.L. and the Departments of Excellence’ program of the Italian Ministry for University and Research (MIUR, 2018-2022 and MUR, 2023-2027) to R.F. L.B. was a FPU predoctoral fellow (FPU13/02400). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033) and the Generalitat de Catalunya through the CERCA program. We are grateful to the CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and a member of the PRB3-ProteoRed (PT17/0019, Instituto de Salud Carlos III and ERDF).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

TFIIIC binding to alu elements controls gene expression via chromatin looping and histone acetylation

  • Ferrari, Roberto
  • De Llobet, Lara Isabel
  • Di Vona, Chiara, 1981-
  • Le Dily, François
  • Vidal Ocabo, Enrique
  • Lloutas, Antonios
  • Quilez Oliete, Javier
  • Jochem, Laura
  • Cuts, Erin
  • Dieci, Giorgio
  • Vannini, Alessandro
  • Teichmann, Martin
  • de la Luna, Susana
  • Beato, Miguel
How repetitive elements, epigenetic modifications, and architectural proteins interact ensuring proper genome expression remains poorly understood. Here, we report regulatory mechanisms unveiling a central role of Alu elements (AEs) and RNA polymerase III transcription factor C (TFIIIC) in structurally and functionally modulating the genome via chromatin looping and histone acetylation. Upon serum deprivation, a subset of AEs pre-marked by the activity-dependent neuroprotector homeobox Protein (ADNP) and located near cell-cycle genes recruits TFIIIC, which alters their chromatin accessibility by direct acetylation of histone H3 lysine-18 (H3K18). This facilitates the contacts of AEs with distant CTCF sites near promoter of other cell-cycle genes, which also become hyperacetylated at H3K18. These changes ensure basal transcription of cell-cycle genes and are critical for their re-activation upon serum re-exposure. Our study reveals how direct manipulation of the epigenetic state of AEs by a general transcription factor regulates 3D genome folding and expression., This work was supported by the Spanish Ministry of Economy and Competitiveness Centro de Excelencia Severo Ochoa 2013–2017 SEV-2012-0208 (to CRG) and BFU2016-76141-P (to S.d.l.L.); ACER (to CRG); Italian Association for Cancer Research (AIRC, grant IG16877 to G.D.); the Cancer Research UK Programme Foundation (CR-UK C47547/A21536 to A.V.); a Wellcome Trust Investigator Award (200818/Z/16/Z to A.V.); and the European Research Council (ERC) under the European Union’s Seventh Framework Programme (FP7/2007–2013/ERC Synergy grant agreement 609989-4DGenome to M.B.). We acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the CERCA Programme/Generalitat de Catalunya , and the Centro de Excelencia Severo Ochoa. The ERC provided funding for the open access charge. The proteomics analyses were performed at the CRG/UPF Proteomics Unit (part of the of Proteored, PRB3; supported by grant PT17/0019 [ISCIII and ERDF]). This work was also supported by the Ligue Contre le Cancer (to M.T.)
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A novel CDC25A/DYRK2 regulatory switch modulates cell cycle and survival

  • Lara-Chica, Maribel
  • Correa-Sáez, Alejandro
  • Jiménez-Izquierdo, Rafael
  • Garrido-Rodríguez, Martín
  • Ponce, Francisco J.
  • Moreno, Rita
  • Morrison, Kimberley
  • Di Vona, Chiara, 1981-
  • Arató, Krisztina, 1981-
  • Jiménez-Jiménez, Carla
  • Morrugares, Rosario
  • Schmitz, M. Lienhard
  • Luna, Susana de la
  • Vega, Laureano de la
  • Calzado, Marco A.
The cell division cycle 25A (CDC25A) phosphatase is a key regulator of cell cycle progression that acts on the phosphorylation status of Cyclin-Cyclin-dependent kinase complexes, with an emergent role in the DNA damage response and cell survival control. The regulation of CDC25A activity and its protein level is essential to control the cell cycle and maintain genomic integrity. Here we describe a novel ubiquitin/proteasome-mediated pathway negatively regulating CDC25A stability, dependent on its phosphorylation by the serine/threonine kinase DYRK2. DYRK2 phosphorylates CDC25A on at least 7 residues, resulting in its degradation independent of the known CDC25A E3 ubiquitin ligases. CDC25A in turn is able to control the phosphorylation of DYRK2 at several residues outside from its activation loop, thus affecting DYRK2 localization and activity. An inverse correlation between DYRK2 and CDC25A protein amounts was observed during cell cycle progression and in response to DNA damage, with CDC25A accumulation responding to the manipulation of DYRK2 levels or activity in either physiological scenario. Functional data show that the pro-survival activity of CDC25A and the pro-apoptotic activity of DYRK2 could be partly explained by the mutual regulation between both proteins. Moreover, DYRK2 modulation of CDC25A expression and/or activity contributes to the DYRK2 role in cell cycle regulation. Altogether, we provide evidence suggesting that DYRK2 and CDC25A mutually control their activity and stability by a feedback regulatory loop, with a relevant effect on the genotoxic stress pathway, apoptosis, and cell cycle regulation., This work was funded by Ministerio de Ciencia e Innovación (SAF2016-75228-R to MAC and BFU2016-76141-P to SdlL) and by Cancer Research UK (C52419/A22869) to LdlV. MLC and ACS were supported by a FPU fellowship (FPU13/03393 and FPU18/00845, respectively) from the Ministerio de Educación y Formación Profesional.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia
  • Barallobre, María-José
  • Di Vona, Chiara
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat, Cristina
  • Arbones, Maria L.
  • Graupera, Mariona
  • Valverde, Miguel A.
  • Luna, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis, This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), ‘‘La Marato´ de TV3’’ to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European Commission FP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Sk1odowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011- 045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011- 11140), and A.F.F. is a Marie Sk1odowska-Curie ESR fellow. We acknowledge the support of the MINECO Centro de Excelencia Severo Ochoa and María de Maeztu Programme and the CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

  • Luna, Jeroni
  • Boni, Jacopo
  • Cuatrecasas, Miriam
  • Bofill-De Ros, Xavier
  • Núñez-Manchón, Estela
  • Gironella, Meritxell
  • Vaquero, Eva C.
  • Arbones, Maria L.
  • Luna, Susana de la
  • Fillat, Cristina
[Background and aims]: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive tumour with a poor prognosis using current treatments. Targeted therapies may offer a new avenue for more effective strategies. Dual-specificity tyrosine regulated kinase 1A (DYRK1A) is a pleiotropic kinase with contradictory roles in different tumours that is uncharacterised in PDAC. Here, we aimed to investigate the role of DYRK1A in pancreatic tumorigenesis. [Design]: We analysed DYRK1A expression in PDAC genetic mouse models and in patient samples. DYRK1A function was assessed with knockdown experiments in pancreatic tumour cell lines and in PDAC mouse models with genetic reduction of Dyrk1a dosage. Furthermore, we explored a mechanistic model for DYRK1A activity. [Results]: We showed that DYRK1A was highly expressed in PDAC, and that its protein level positively correlated with that of c-MET. Inhibition of DYRK1A reduced tumour progression by limiting tumour cell proliferation. DYRK1A stabilised the c-MET receptor through SPRY2, leading to prolonged activation of extracellular signal-regulated kinase signalling. [Conclusions]: These findings reveal that DYRK1A contributes to tumour growth in PDAC, at least through regulation of c-MET accumulation, suggesting that inhibition of DYRK1A could represent a novel therapeutic target for PDAC., This work was supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) (BIO2014-57716-C2-2-R, BIO2017-89754-C2-2R to CF and BFU2016-76141-P to SL), and receives partial support from the Generalitat de Catalunya (SGR14/248 to CF and SGR14/674 to SL). CIBER de Enfermedades Raras and de Enfermedades Hepáticas y Digestivas are initiatives of the Instituto de Salud Carlos III (ISCIII). The group of CF is partially financed by the ISCIII (IIS10/00014), co-financed by Fondo Europeo de Desarrollo Regional (FEDER), and acknowledges the support of the COST Action BM1204 EUPancreas. MG acknowledges grant PI17/01003 from ISCIII.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

  • Arranz, Juan
  • Balducci, Elisa
  • Arató, Krisztina
  • Sánchez-Elexpuru, Gentzane
  • Najas, Sònia
  • Parras, Alberto
  • Rebollo, Elena
  • Pijuan, Isabel
  • Erb, Ionas
  • Verde, Gaetano
  • Sahún, Ignasi
  • Barallobre, María-José
  • Lucas, José Javier
  • Sánchez, Marina P.
  • Luna, Susana de la
  • Arbones, Maria L.
Autism spectrum disorders are early onset neurodevelopmental disorders characterized by deficits in social communication and restricted repetitive behaviors, yet they are quite heterogeneous in terms of their genetic basis and phenotypic manifestations. Recently, de novo pathogenic mutations in DYRK1A, a chromosome 21 gene associated to neuropathological traits of Down syndrome, have been identified in patients presenting a recognizable syndrome included in the autism spectrum. These mutations produce DYRK1A kinases with partial or complete absence of the catalytic domain, or they represent missense mutations located within this domain. Here, we undertook an extensive biochemical characterization of the DYRK1A missense mutations reported to date and show that most of them, but not all, result in enzymatically dead DYRK1A proteins. We also show that haploinsufficient Dyrk1a+/− mutant mice mirror the neurological traits associated with the human pathology, such as defective social interactions, stereotypic behaviors and epileptic activity. These mutant mice present altered proportions of excitatory and inhibitory neocortical neurons and synapses. Moreover, we provide evidence that alterations in the production of cortical excitatory neurons are contributing to these defects. Indeed, by the end of the neurogenic period, the expression of developmental regulated genes involved in neuron differentiation and/or activity is altered. Therefore, our data indicate that altered neocortical neurogenesis could critically affect the formation of cortical circuits, thereby contributing to the neuropathological changes in DYRK1A haploinsufficiency syndrome., This work was supported by grants from the Spanish Ministry of Economia, Industria y Competitividad (MINECO) (BFU2016-81887-REDT, SAF2013-46676-P and SAF2016-77971-R to M.L.A. and BFU2013-44513 and BFU2016-76141 to S.L.), the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), and the Fundación Alicia Koplowitz (Spain). The group of S.L. acknowledges the support of the MINECO Centro de Excelencia Severo Ochoa Programme and of the CERCA Programme (Generalitat de Catalunya). G.S-E. and M.P.S. acknowledge the support of the National Institute of Neurological Disorders and Stroke of the National Institutes of Health(USA) (P01NS097197) and the Spanish Instituto de Salud Carlos III (ISCIII), (PI13/00865, Fondo Europeo de Desarrollo Regional -FEDER “A way of making Europe”, Spain). M.J.B. is supported by the CIBERER, an initiative of the ISCIII. J.A., E.B. and S.N. were supported by MINECO predoctoral fellowships (AP2012-3064 and BES2011-047472) and G.S-E. by a predoctoral fellowship from the Fundación Conchita Rábago, Spain.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The DYRK family of kinases in cancer: molecular functions and therapeutic opportunities

  • Boni, Jacopo, 1987-
  • Rubio Pérez, Carlota, 1990-
  • López Bigas, Núria
  • Fillat i Fonts, Cristina
  • Luna, Susana de la
DYRK (dual-specificity tyrosine-regulated kinases) are an evolutionary conserved family of protein kinases with members from yeast to humans. In humans, DYRKs are pleiotropic factors that phosphorylate a broad set of proteins involved in many different cellular processes. These include factors that have been associated with all the hallmarks of cancer, from genomic instability to increased proliferation and resistance, programmed cell death, or signaling pathways whose dysfunction is relevant to tumor onset and progression. In accordance with an involvement of DYRK kinases in the regulation of tumorigenic processes, an increasing number of research studies have been published in recent years showing either alterations of DYRK gene expression in tumor samples and/or providing evidence of DYRK-dependent mechanisms that contribute to tumor initiation and/or progression. In the present article, we will review the current understanding of the role of DYRK family members in cancer initiation and progression, providing an overview of the small molecules that act as DYRK inhibitors and discussing the clinical implications and therapeutic opportunities currently available., J.B. is an FPI predoctoral fellow (BES-2014-069983). De la Luna’s lab is supported by grants from the Spanish Ministry of Science and Innovation (BFU2016-76141-P, AEI/FEDER), the AGAUR grant from Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya (SGR14/674) and the CIBER de Enfermedades Raras. We thank La Marato of TV3 for its support to our research in cancer. We also acknowledge the support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the support of the CERCA Programme/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

DYRK1A kinase positively regulates angiogenic responses in endothelial cells

  • Rozen, Esteban J.
  • Roewenstrunk, Julia Maria, 1981-
  • Barallobre, María José
  • Di Vona, Chiara, 1981-
  • Jung, Carole
  • Figueiredo, Ana F.
  • Luna, Jeroni
  • Fillat i Fonts, Cristina
  • Arbonés de Rafael, Maria Lourdes, 1959-
  • Graupera, Mariona
  • Valverde, M. A. (Miguel Ángel), 1963-
  • Luna Gargantilla, Susana de la
Angiogenesis is a highly regulated process essential for organ development and maintenance, and its deregulation contributes to inflammation, cardiac disorders, and cancer. The Ca2+/nuclear factor of activated T cells (NFAT) signaling pathway is central to endothelial cell angiogenic responses, and it is activated by stimuli like vascular endothelial growth factor (VEGF) A. NFAT phosphorylation by dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs) is thought to be an inactivating event. Contrary to expectations, we show that the DYRK family member DYRK1A positively regulates VEGF-dependent NFAT transcriptional responses in primary endothelial cells. DYRK1A silencing reduces intracellular Ca2+ influx in response to VEGF, which dampens NFAT activation. The effect is exerted at the level of VEGFR2 accumulation leading to impairment in PLCγ1 activation. Notably, Dyrk1a heterozygous mice show defects in developmental retinal vascularization. Our data establish a regulatory circuit, DYRK1A/ Ca2+/NFAT, to fine-tune endothelial cell proliferation and angiogenesis., This work was supported by the Spanish Ministry of Economy and Competitiveness (MINECO grants BFU2013-44513 and BFU2016-76141-P to S.L., SAF2015-69762R to M.A.V., SAF2014-59950-P to M.G., BIO2014-57716-C2-R to C.F., and SAF2016-77971-R to M.L.A.), “La Marató de TV3” to S.L., the Instituto de Salud Carlos III (IIS10/00014 to C.F. and RD12/0042/0014 to M.A.V.), FEDER Funds to M.A.V., the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674), the European CommissionFP7/2007-2013, and 2020 Research and Innovation Programmes (grant agreement 317250 and Marie Skłodowska-Curie grant agreement 675392). E.J.R., J.L., and M.J.B. are supported by CIBERER, J.R. is an FPI predoctoral fellow (BES-2011-045867), C.J. is a Juan de la Cierva postdoctoral researcher (JCI-2011-11140), and A.F.F. is a Marie Skłodowska-Curie ESR fellow.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

TFIIIC binding to alu elements controls gene expression via chromatin looping and histone acetylation

  • Ferrari, Roberto
  • De Llobet, Lara Isabel
  • Di Vona, Chiara, 1981-
  • Le Dily, François
  • Vidal Ocabo, Enrique
  • Lloutas, Antonios
  • Quilez Oliete, Javier
  • Jochem, Laura
  • Cuts, Erin
  • Dieci, Giorgio
  • Vannini, Alessandro
  • Teichmann, Martin
  • de la Luna, Susana
  • Beato, Miguel
How repetitive elements, epigenetic modifications, and architectural proteins interact ensuring proper genome expression remains poorly understood. Here, we report regulatory mechanisms unveiling a central role of Alu elements (AEs) and RNA polymerase III transcription factor C (TFIIIC) in structurally and functionally modulating the genome via chromatin looping and histone acetylation. Upon serum deprivation, a subset of AEs pre-marked by the activity-dependent neuroprotector homeobox Protein (ADNP) and located near cell-cycle genes recruits TFIIIC, which alters their chromatin accessibility by direct acetylation of histone H3 lysine-18 (H3K18). This facilitates the contacts of AEs with distant CTCF sites near promoter of other cell-cycle genes, which also become hyperacetylated at H3K18. These changes ensure basal transcription of cell-cycle genes and are critical for their re-activation upon serum re-exposure. Our study reveals how direct manipulation of the epigenetic state of AEs by a general transcription factor regulates 3D genome folding and expression., This work was supported by the Spanish Ministry of Economy and Competitiveness Centro de Excelencia Severo Ochoa 2013–2017 SEV-2012-0208 (to CRG) and BFU2016-76141-P (to S.d.l.L.); ACER (to CRG); Italian Association for Cancer Research (AIRC, grant IG16877 to G.D.); the Cancer Research UK Programme Foundation (CR-UK C47547/A21536 to A.V.); a Wellcome Trust Investigator Award (200818/Z/16/Z to A.V.); and the European Research Council (ERC) under the European Union’s Seventh Framework Programme (FP7/2007–2013/ERC Synergy grant agreement 609989-4DGenome to M.B.). We acknowledge the support of the Spanish Ministry of Science, Innovation, and Universities to the EMBL partnership, the CERCA Programme/Generalitat de Catalunya , and the Centro de Excelencia Severo Ochoa. The ERC provided funding for the open access charge. The proteomics analyses were performed at the CRG/UPF Proteomics Unit (part of the of Proteored, PRB3; supported by grant PT17/0019 [ISCIII and ERDF]). This work was also supported by the Ligue Contre le Cancer (to M.T.)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Loss of the DYRK1A Protein Kinase Results in the Reduction in Ribosomal Protein Gene Expression, Ribosome Mass and Reduced Translation

  • Di Vona, Chiara, 1981-
  • Barba Moreno, Laura, 1989-
  • Ferrari, Roberto
  • Luna, Susana de la
Ribosomal proteins (RPs) are evolutionary conserved proteins that are essential for protein translation. RP expression must be tightly regulated to ensure the appropriate assembly of ribosomes and to respond to the growth demands of cells. The elements regulating the transcription of RP genes (RPGs) have been characterized in yeast and Drosophila, yet how cells regulate the production of RPs in mammals is less well understood. Here, we show that a subset of RPG promoters is characterized by the presence of the palindromic TCTCGCGAGA motif and marked by the recruitment of the protein kinase DYRK1A. The presence of DYRK1A at these promoters is associated with the enhanced binding of the TATA-binding protein, TBP, and it is negatively correlated with the binding of the GABP transcription factor, establishing at least two clusters of RPGs that could be coordinately regulated. However, DYRK1A silencing leads to a global reduction in RPGs mRNAs, pointing at DYRK1A activities beyond those dependent on its chromatin association. Significantly, cells in which DYRK1A is depleted have reduced RP levels, fewer ribosomes, reduced global protein synthesis and a smaller size. We therefore propose a novel role for DYRK1A in coordinating the expression of genes encoding RPs, thereby controlling cell growth in mammals., This research was supported by the Spanish Ministry of Science and Innovation (BFU2016-76141-P, PID2019-107185GB-I00, AEI/FEDER) and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement de la Generalitat de Catalunya (grant number 2021SGR01229) to S.d.l.L. and the Departments of Excellence’ program of the Italian Ministry for University and Research (MIUR, 2018-2022 and MUR, 2023-2027) to R.F. L.B. was a FPU predoctoral fellow (FPU13/02400). We acknowledge the support of the Spanish Ministry of Science and Innovation through the Centro de Excelencia Severo Ochoa (CEX2020-001049-S, MCIN/AEI/10.13039/501100011033) and the Generalitat de Catalunya through the CERCA program. We are grateful to the CRG/UPF Proteomics Unit, which is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech) and a member of the PRB3-ProteoRed (PT17/0019, Instituto de Salud Carlos III and ERDF).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A novel CDC25A/DYRK2 regulatory switch modulates cell cycle and survival

  • Lara-Chica, Maribel
  • Correa-Sáez, Alejandro
  • Jiménez-Izquierdo, Rafael
  • Garrido-Rodríguez, Martín
  • Ponce, Francisco J.
  • Moreno, Rita
  • Morrison, Kimberley
  • Di Vona, Chiara, 1981-
  • Arató, Krisztina, 1981-
  • Jiménez-Jiménez, Carla
  • Morrugares, Rosario
  • Schmitz, M. Lienhard
  • Luna, Susana de la
  • Vega, Laureano de la
  • Calzado, Marco A.
The cell division cycle 25A (CDC25A) phosphatase is a key regulator of cell cycle progression that acts on the phosphorylation status of Cyclin-Cyclin-dependent kinase complexes, with an emergent role in the DNA damage response and cell survival control. The regulation of CDC25A activity and its protein level is essential to control the cell cycle and maintain genomic integrity. Here we describe a novel ubiquitin/proteasome-mediated pathway negatively regulating CDC25A stability, dependent on its phosphorylation by the serine/threonine kinase DYRK2. DYRK2 phosphorylates CDC25A on at least 7 residues, resulting in its degradation independent of the known CDC25A E3 ubiquitin ligases. CDC25A in turn is able to control the phosphorylation of DYRK2 at several residues outside from its activation loop, thus affecting DYRK2 localization and activity. An inverse correlation between DYRK2 and CDC25A protein amounts was observed during cell cycle progression and in response to DNA damage, with CDC25A accumulation responding to the manipulation of DYRK2 levels or activity in either physiological scenario. Functional data show that the pro-survival activity of CDC25A and the pro-apoptotic activity of DYRK2 could be partly explained by the mutual regulation between both proteins. Moreover, DYRK2 modulation of CDC25A expression and/or activity contributes to the DYRK2 role in cell cycle regulation. Altogether, we provide evidence suggesting that DYRK2 and CDC25A mutually control their activity and stability by a feedback regulatory loop, with a relevant effect on the genotoxic stress pathway, apoptosis, and cell cycle regulation., This work was funded by Ministerio de Ciencia e Innovación (SAF2016-75228-R to MAC and BFU2016-76141-P to SdlL) and by Cancer Research UK (C52419/A22869) to LdlV. MLC and ACS were supported by a FPU fellowship (FPU13/03393 and FPU18/00845, respectively) from the Ministerio de Educación y Formación Profesional.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response

  • Roewenstrunk, Julia Maria, 1981-
  • Di Vona, Chiara, 1981-
  • Chen, Jie
  • Borràs, Eva
  • Dong, Chao
  • Arató, Krisztina, 1981-
  • Sabidó Aguadé, Eduard, 1981-
  • Huen, Michael S. Y.
  • Luna Gargantilla, Susana de la
Dysregulation of the DYRK1A protein kinase has been associated with human disease. On the one hand, its overexpression in trisomy 21 has been linked to certain pathological traits of Down syndrome, while on the other, inactivating mutations in just one allele are responsible for a distinct yet rare clinical syndrome, DYRK1A haploinsufficiency. Moreover, altered expression of this kinase may also provoke other human pathologies, including cancer and diabetes. Although a few DYRK1A substrates have been described, its upstream regulators and downstream targets are still poorly understood, an information that could shed light on the functions of DYRK1A in the cell. Here, we carried out a proteomic screen using antibody-based affinity purification coupled to mass spectrometry to identify proteins that directly or indirectly bind to endogenous DYRK1A. We show that the use of a cell line not expressing DYRK1A, generated by CRISPR/Cas9 technology, was needed in order to discriminate between true positives and non-specific interactions. Most of the proteins identified in the screen are novel candidate DYRK1A interactors linked to a variety of activities in the cell. The in-depth characterization of DYRK1A's functional interaction with one of them, the E3 ubiquitin ligase RNF169, revealed a role for this kinase in the DNA damage response. We found that RNF169 is a DYRK1A substrate and we identified several of its phosphorylation sites. In particular, one of these sites appears to modify the ability of RNF169 to displace 53BP1 from sites of DNA damage. Indeed, DYRK1A depletion increases cell sensitivity to ionizing irradiation. Therefore, our unbiased proteomic screen has revealed a novel activity of DYRK1A, expanding the complex role of this kinase in controlling cell homeostasis., This work was supported by grants from the Spanish Ministry of Economy, Industry and Competitiveness (MEIC) BFU2013-44513 and BFU2016-76141-P, and the Secretariat of Universities and Research-Generalitat de Catalunya (2014SGR674). Proteomic analysis was carried out at the CRG/UPF Proteomics Unit, a member of the ProteoRed PRB3 consortium that is supported by grant PT17/0019 of the PE I + D + i 2013–2016 from the Instituto de Salud Carlos III (ISCIII) and ERDF. J.R. is a FPI predoctoral fellow (BES-2011-045867). We also acknowledge the support of the Generalitat de Catalunya: CERCA Programme and Grups de Recerca Reconocida Programme (2017SGR595 and 2017SGR1163)